Submitted:
24 July 2023
Posted:
25 July 2023
You are already at the latest version
Abstract
Objectives: Studies on the association between non-steroidal anti-inflammatory drugs (NSAIDs) and major adverse cardiovascular events (MACE) in the Arabian Gulf are scarce. The aim of this study was to evaluate the association between NSAIDs use and MACE in acute coronary syndrome (ACS) patients in the Arabian Gulf region. Methods: Data was analyzed from 3,007 consecutive patients diagnosed with ACS admitted to 29 hospitals in four Arabian Gulf countries from January 2012 to January 2013 as well as being on prior NSAIDs use during the index admission. MACE included stroke/transient ischemic attacks (TIAs), myocardial infarction (MI), all-cause mortality and readmissions for cardiac reasons. Results: The overall mean age of the cohort was 62 ± 12 years and 9.6% (n = 290) of the patients were on prior NSAID use during the index admission. At 12-months follow-up, after adjusting for confounding factors, those on NSAIDs were significantly more likely to have had MACE (adjusted OR (aOR), 1.89; 95% confidence interval (CI): 1.44-2.48; p < 0.001). Specifically, the higher event rates observed were stroke/TIA (aOR, 2.50; 95% CI: 1.51-4.14; p < 0.001) and readmissions for cardiac reasons (aOR, 2.09; 95% CI: 1.59-2.74; p < 0.001) but not MI (aOR, 1.26; 95% CI: 0.80-1.99; p = 0.320) and all-cause mortality (aOR, 0.79; 95% CI: 0.46-1.34; p = 0.383). Conclusions: NSAIDs use was associated with significant stroke/TIA events as well as readmissions for cardiac reasons. However, NSAIDs were not associated with increased MI or all-cause mortality rates in ACS patients in the Arabian Gulf.
Keywords:
non-steroidal anti-inflammatory drug
; stroke
; acute coronary syndrome
; myocardial infarction
; mortality
; readmission
; Arabian Gulf
1. Introduction
Acute coronary syndrome (ACS) is one of the leading causes of morbidity and mortality in Asia as well as globally [1,2] accounting for approximately seven million deaths and 129 million disability-adjusted life years (DALYs) annually worldwide [3,4]. ACS is also associated with significant economic burden on both direct and indirect healthcare costs with economic analyses suggesting that hospitalizations and readmissions for ACS accounts for 60-90% of total annual health care costs [5,6,7].
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of a group of medications that is widely used and easily available over the counter (OTC). More than 70 million prescriptions for NSAIDs are written annually, and taking into account OTC medications, 30 billion doses of NSAIDs are consumed annually in the United States alone [8]. They are used, in the short- and long-term, for a variety of indications including pain and rheumatoid arthritis, amongst many others. Besides gastrointestinal bleeding, which is partially alleviated by the use of proton pump inhibitors (PPIs), NSAIDs have also been associated with major adverse cardiovascular events (MACE) including stroke [9,10]. The cardiovascular risk may not only be limited to non-selective NSAIDS but also to selective cyclooxygenase 2 (COX-2) inhibitors [11].
There is currently limited research on the use of NSAIDs in ACS population in the Arabian Gulf. Hence, the aim of this study was to evaluate the association between NSAIDs use and MACE events including readmissions for cardiac reasons in ACS patients in the Arabian Gulf.
2. Methods
The Gulf COAST registry methods have already been previously reported [12]. In summary, the Gulf COAST registry was a prospective, multicenter, multinational, longitudinal, cohort study of consecutive citizens, from the Arabian Gulf (Bahrain, Kuwait, Oman and United Arab Emirates), admitted to 29 hospitals with a diagnosis of ACS from January 2012 to January 2013. The registry enrolled a total of 4,044 patients who were ≥18 years of age with ACS diagnosed according to American College of Cardiology (ACC) clinical data standards [13]. Apart from excluding non-citizens as well as those who were not willing/able to provide consent, there were no other exclusion criteria. The study was approved by the local institutional ethics committees of participating centers in the four Arabian Gulf countries.
Data collected included patient demographics (age, gender, employment status, marital status, education status, health insurance, body mass index (BMI), tobacco and alcohol use), medical history and risk factors related to MACE, prior medication use, laboratory data, clinical presentation and management during hospital stay including medications, reperfusion therapy and procedures and discharge medications. Follow up was performed at 12-months from the date of enrolment and was carried out by clinic visits or telephone interviews.
The main predictor variable was NSAID use while the outcomes collected included 12-months cumulative stroke/transient ischemic attack (TIA), myocardial infarction (MI), all-cause mortality and readmissions for cardiac reasons as well as overall MACE.
2.1. Statistical Analysis
For categorical variables, frequencies and percentages were reported. Differences among groups were analyzed using Pearson’s χ2 tests (or Fisher’s exact tests for expected cells of <5). For continuous variables, mean and standard deviation were used to present the data while analyses were performed using Student’s t-test. Continuous variables that were not normally distributed were summarized as median and interquartile range and analyses conducted using Wilcoxon-Mann-Whitney tests. The association between NSAID use and MACE (stroke/TIA, MI, all-cause mortality, readmissions for cardiac reasons and overall MACE) was evaluated by multivariate logistic regression utilizing the simultaneous method and adjusting for GRACE risk score for in-hospital mortality, which has been validated in an Arabian Gulf ACS Registry [14]. Apart from GRACE risk score variables (which is derived from age, heart rate, systolic blood pressure (BP), serum creatinine, cardiac arrest at admission, ST segment deviation on EKG, abnormal cardiac enzymes and Killip class), the logistic models were also adjusted for gender, smoking status, marital status, employment status, education status, BMI, diabetes mellitus, peripheral artery disease, percutaneous coronary intervention (PCI)/coronary artery bypass graft (CABG), prior event and use of evidence-based cardiac medications at hospital discharge (aspirin, clopidogrel, beta blocker, statin, angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)).
The goodness-of-fit of the multivariable logistic models was examined using the Hosmer & Lemeshow goodness-of-fit statistic [15] as well as the C-index [16]. An a priori two-tailed level of significance was set at the 0.05 level. Statistical analyses were conducted using STATA version 16.1 (StataCorp, 2013, Stata Statistical Software, College Station, TX, USA).
3. Results
Out of the 4,044 subjects enrolled by the Gulf COAST registry, the present analysis only included patients with non-missing NSAID information (N = 3,007). A total of 9.6% (n = 290) of the patients were on prior NSAID use during the index admission. The overall mean age of the cohort was 62 ± 12 years of which 62% (n = 1,851) were males. A total of 22% (n = 647) of the patients were employed and 83% (n = 2,495) were married. Thirty four percent of the patients (n = 1,037) were current or prior smokers and 2.9% (n = 87) were alcohol consumers. Comorbid conditions were common, particularly hypertension (81%; n = 2,433), dyslipidaemia (70%; n = 2,101) and diabetes mellitus (63%; n = 1,903).
As shown in Table 1, those on NSAIDs (compared to those that were not on NSAIDs) were more likely to be female (44% vs 38%; p = 0.049), educated (54% vs 46%; p = 0.013), associated with dyslipidaemia (77% vs 69%; p = 0.009), hypertension (86% vs 80%; p = 0.016) and heart failure (20% vs 14%; p = 0.012). However, those on NSAIDs were less likely to be associated with diabetes mellitus (57% vs 64%; p = 0.018) and non ST-elevation MI (41% vs 52%; p < 0.001).
Table 2 shows medication utilization prior to admission and post-discharge stratified by NSAIDs use. Prior to the index admission, those on NSAIDs were also more likely to have been on aspirin (85% vs 79%; p = 0.023) and clopidogrel (35% vs 28%; p = 0.015). While 98% (n = 2,705) of the cohort was treated optimally with the dual antiplatelet combination (aspirin and clopidogrel concurrently), only 52% (n = 1427) of the patients were prescribed the 5-drug regimen (aspirin, clopidogrel, ACEI/ARB, statin, beta blocker) concurrently which was significantly higher among those on NSAIDs than those not on NSAIDs (62% vs 51%; p = 0.001).
The overall MACE rate was 41.1% (n = 1,195) with significant differences among the groups as shown in Table 3. Adjusting for demographic and clinical characteristics as well as socioeconomic measures (insurance type, employment, education and marital status), at 12-months follow-up, those on NSAIDs were significantly more likely to have had MACE (adjusted OR (aOR), 1.89; 95% confidence interval (CI): 1.44-2.48; p < 0.001). The higher event rates were specifically observed in stroke/TIA (aOR, 2.50; 95% CI: 1.51-4.14; p < 0.001) and in readmissions for cardiac reasons (aOR, 2.09; 95% CI: 1.59-2.74; p < 0.001) but not in MI (aOR, 1.26; 95% CI: 0.80-1.99; p = 0.320) and 12-months all-cause mortality (aOR, 0.79; 95% CI: 0.46-1.34; p = 0.383).
4. Discussion
To the best of our knowledge, this is the only study in the Arabian Gulf, to have evaluated the association between NSAIDs use and the development of MACE in ACS patients. At 12-months follow-up, those on prior use of NSAIDs were associated with increased risk of stroke/TIA events and readmissions for cardiac reasons when compared to those that were not on NSAIDs. However, NSAIDs use was not associated with increased MI or all-cause mortality rates in ACS patients in the Arabian Gulf.
Similar to the current findings, a number of other meta-analyses and review articles have also reported that the use of various types of NSAIDs (both non-selective as well as COX-2 inhibitors) are associated with the development of stroke/TIA events compered to patients not using NSAIDs.[17,18,19,20,21,22] The potential mechanisms for NSAID-associated increase in stroke risk is hypothesized to be due to vasoconstriction secondary to inhibition of prostacyclin-induced vasodilation, hypertension induced by direct renal effects on sodium excretion leading to volume expansion and thrombosis due to prostaglandin-mediated platelet aggregation.[23] This study did not document the actual types of NSAIDs used and this shortcoming may pose a significant limitation as some have been more associated with stroke/TIA events than others.[18] Furthermore, this study also did not report the duration of use of NSAIDs. However, no safe window on concomitant use of NSAIDs has been reported, with even a short-term (0-3 days) use has been associated with increased risk of bleeding compared with no NSAIDs use.[24]
Our findings showed a significant association between the use of NSAIDs in patients with ACS and readmissions due to cardiac reasons which can be partly explained by the type, dose and duration of use of NSAIDs which were not documented in our study. Furthermore, the risk of cardiac complication is higher in the first week of NSAIDs use, but not for all type of NSAIDs as reported in some studies.[25] A population-based matched case–control study in Finland[26] showed that hospitalizations due to myocardial infarction in patients using NSAIDs accounted for 17,000 hospitalizations annually. The current study did not show any differences in myocardial infarction rates between the groups not only at baseline (Table 1) but also at 1-year follow-up (Table 3), however, the NSAIDs group was associated with higher prevalence of hypertension and heart failure (Table 1) which has been reported as the main reason behind readmissions in ACS patients.[27]
In conclusion, NSAIDs use was associated with significant increase in stroke/TIA events as well as readmissions for cardiac reasons. However, NSAIDs were not associated with increased MI or all-cause mortality rates in ACS patients in the Arabian Gulf.
5. Limitations
As this was a retrospective study and the fact that the analyses were also adjusted for various confounding factors, bias could still have existed between the groups as we were not able to control for unmeasured confounding variables. Instead of all-cause mortality, it would have been more pertinent to have reported cardiovascular mortality. Even though all types of NSAIDs are implicated in cardiovascular events, it would have been more informative to have reported the different types of NSAIDs. Furthermore, NSAIDs use was only reported during the index hospital admission, they could have been stopped or changed during the 1-year follow-up. However, as reported earlier, there is no safe window on concomitant use of NSAIDs with even a short-term period of a few days use has been associated with increased risk of bleeding.[24] A total of 3.2% (n = 97) of the subjects were lost to follow-up at 12-months and this could have biased the outcomes; however, there were no significant differences in the demographic and clinical characteristics between the patients that were lost to follow-up against the group that remained during the 12-months follow-up period (Table 4).
Funding
Gulf COAST is an investigator-initiated study that was supported by AstraZeneca and Kuwait University (project code XX02/11). Neither Kuwait University nor AstraZeneca had any role in the study design, data collection, data analysis, or writing the article.
Institutional Board approval
The study was approved by the local institutional ethics committees of participating centers in the four Arabian Gulf countries (Kuwait, Joint Committee for the Protection of Human Subjects in Research, VDR/JC/89, 13/10/2011; Oman, Ethical Review & Approve Committee, Ministry of Health Research, MH/DGP/R&S/PROPOSAL_APPROVED/1/2012, 9/1/2012; Bahrain, Secondary Care Medical Research Subcommittee, Ministry of Health, 23/12/2011; Abu Dhabi UAE, Institutional Review Board/Research Ethics Committee, Sheikh Khalifa Medical City, REC-24.11.2011 [RS 189], 24/11/2011; Abu Dhabi UAE, Institutional Review Board, Medical Services Corps, General Head Quarters Armed Forces, 18/11/2011; Al Ain UAE, Al Ain Medical District Human Research Ethics Committee, Faculty of Medicine & Health Sciences, United Arab Emirates University, Protocol No. 11/48, 24/11/2011; Dubai UAE, Medical Research Committee, Dubai Health Authority, MRC-11/2011_2, 30/11/202011).
Data Availability Statement
Data was anonymized for this study. All data are available upon request to the corresponding author.
Acknowledgements
The authors would like to thank the patients, physicians, nurses, and support staff who participated in the Gulf COAST Registry for their invaluable cooperation.
Conflicts of Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
- Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015, 386, 743–800. [Google Scholar] [CrossRef]
- Ohira T, Iso H. Cardiovascular disease epidemiology in Asia: An overview. Circ J. 2013, 77, 1646–1652.
- Lozano R, Naghavi M, Foreman K; et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380, 2095–2128. [Google Scholar] [CrossRef] [PubMed]
- Murray CJ, Vos T, Lozano R; et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380, 2197–2223. [Google Scholar] [CrossRef] [PubMed]
- Page RL 2nd, Ghushchyan V, Gifford B; et al. The economic burden of acute coronary syndromes for employees and their dependents: Medical and productivity costs. J Occup Environ Med. 2013, 55, 761–767. [Google Scholar] [CrossRef]
- Johnston SS, Curkendall S, Makenbaeva D; et al. The direct and indirect cost burden of acute coronary syndrome. J Occup Environ Med. 2011, 53, 2–7. [Google Scholar] [CrossRef]
- Zhao Z, Winget M. Economic burden of illness of acute coronary syndromes: Medical and productivity costs. BMC Health Serv Res 2011, 11, 35. [CrossRef]
- Wiegand TJ, Vernetti CM. Nonsteroidal Anti-inflammatory Drug (NSAID) Toxicity. Medscape 2020. Available at:. Available online: https://emedicine.medscape.com/article/816117-print (accessed on 14 July 2020).
- Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: Latest evidence and clinical implications. Ther Adv Drug Saf. 2017, 8, 173–182. [Google Scholar] [CrossRef]
- Bally M, Dendukuri N, Rich B; et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017, 357, j1909. [Google Scholar]
- Park K, Bavry AA. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014, 10, 25–32. [Google Scholar]
- Zubaid M, Thani KB, Rashed W, et al; Gulf COAST investigators Design and Rationale of Gulf locals with Acute Coronary Syndrome Events (Gulf Coast) Registry. Open Cardiovasc Med J. 2014, 8, 88–93. [Google Scholar] [CrossRef] [PubMed]
- Weintraub WS, Karlsberg RP, Tcheng JE; et al. ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. J Am Coll Cardiol. 2011, 58, 202–222. [Google Scholar] [CrossRef] [PubMed]
- Panduranga P, Sulaiman K, Al-Zakwani I; et al. Utilization and determinants of in-hospital cardiac catheterization in patients with acute coronary syndrome from the Middle East. Angiology. 2010, 61, 744–750. [Google Scholar] [CrossRef] [PubMed]
- Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982, 115, 92–106. [Google Scholar] [CrossRef]
- Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143, 29–36. [Google Scholar] [CrossRef]
- Schink T, Kollhorst B, Varas Lorenzo C; et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS ONE. 2018, 13, e0203362. [Google Scholar]
- Varga Z, Sabzwari SRA, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus. 2017, 9, e1144. [Google Scholar]
- Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM; et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ. 2011, 342, c7086. [Google Scholar] [CrossRef]
- Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006, 332, 1302–1308. [Google Scholar] [CrossRef]
- Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L; et al. Stroke risk and NSAIDs: A systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011, 20, 1225–1236. [Google Scholar] [CrossRef]
- Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA; et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet. 2013, 382, 769–779. [Google Scholar] [CrossRef] [PubMed]
- Fitzgerald, GA. Coxibs and cardiovascular disease. N Engl J Med. 2004, 21, 1709–1711. [Google Scholar] [CrossRef] [PubMed]
- Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbøl E, Sørensen R, Hansen ML, Køber L, Torp-Pedersen C, Lamberts M. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015, 313, 805–814. [Google Scholar] [CrossRef]
- Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ. 2017, 357, j1909. [Google Scholar]
- Helin-Salmivaara A, Virtanen A, Vesalainen R, Grönroos JM, Klaukka T, Idänpään-Heikkilä JE, Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: A nationwide case-control study from Finland. Eur Heart J. 2006, 27, 1657–1663. [Google Scholar] [CrossRef] [PubMed]
- Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Arch Intern Med. 2005, 165, 978–984. [Google Scholar] [CrossRef]
Table 1.
Demographic and clinical characteristics of the acute coronary syndrome cohort stratified by non-steroidal anti-inflammatory drug (NSAID) use.
Table 1.
Demographic and clinical characteristics of the acute coronary syndrome cohort stratified by non-steroidal anti-inflammatory drug (NSAID) use.
| Characteristic, n (%) unless specified otherwise |
All (N = 3,007) |
NSAID use | p-value | ||
|---|---|---|---|---|---|
| No (n = 2,717) |
Yes (n = 290) |
||||
| Demographic | |||||
| Age, mean±SD, years | 62±12 | 62±12 | 63±12 | 0.124 | |
| Female gender | 1,156 (38%) | 1,029 (38%) | 127 (44%) | 0.049 | |
| Educated | 1,410 (47%) | 1,254 (46%) | 156 (54%) | 0.013 | |
| Employed | 647 (22%) | 592 (22%) | 55 (19%) | 0.266 | |
| Married | 2,495 (83%) | 2,252 (83%) | 243 (84%) | 0.696 | |
| BMI, mean±SD, kg/m2 | 29.1±7.0 | 29.1±7.1 | 28.7±6.3 | 0.305 | |
| Smoking (current or prior) | 1,037 (34%) | 939 (35%) | 98 (34%) | 0.794 | |
| Alcohol | 87 (2.9%) | 75 (2.8%) | 12 (4.1%) | 0.183 | |
| Past medical history | |||||
| Prior MI | 1,026 (34%) | 933 (34%) | 93 (32%) | 0.438 | |
| Dyslipidemia | 2,101 (70%) | 1,879 (69%) | 222 (77%) | 0.009 | |
| Premature CAD | 446 (15%) | 405 (15%) | 41 (14%) | 0.726 | |
| Hypertension | 2,433 (81%) | 2,183 (80%) | 250 (86%) | 0.016 | |
| Heart failure | 441 (15%) | 384 (14%) | 57 (20%) | 0.012 | |
| Diabetes mellitus | 1,903 (63%) | 1,738 (64%) | 165 (57%) | 0.018 | |
| Stroke/TIA | 274 (9.1%) | 254 (9.0%) | 29 (10%) | 0.580 | |
| Clinical (parameters) at presentation | |||||
| HR, mean±SD, bpm | 86±21 | 86±21 | 85±22 | 0.229 | |
| SBP, mean±SD, mmHg | 142±28 | 142±28 | 143±29 | 0.519 | |
| DBP, mean±SD, mmHg | 80±16 | 80±16 | 80±17 | 0.800 | |
| Crea, p50 (IQR), µmol/L | 86 (68-113) | 86 (68-113) | 85 (68-104) | 0.772 | |
| LVEF, mean±SD, % | 49±13 | 48±13 | 50±13 | <0.001 | |
| GRACE risk, mean±SD | 130±42 | 130±42 | 130±43 | 0.789 | |
| CRUSADE risk score | 38±15 | 38±15 | 38±15 | 0.735 | |
| Major bleed | 62 (2.1%) | 54 (2.0%) | 8 (2.8%) | 0.380 | |
| Killip class | 0.320 | ||||
| I – no heart failure | 2270 (75%) | 2063 (76%) | 207 (71%) | ||
| II – rales | 457 (15%) | 403 (15%) | 54 (19%) | ||
| III – pulmonary edema | 250 (8.3%) | 224 (8.2%) | 26 (9.0%) | ||
| IV – cardiogenic shock | 30 (1.0%) | 27 (1.0%) | 3 (1.0%) | ||
| Discharged diagnosis* |
<0.001 |
||||
| LBBB MI | 19 (0.7%) | 16 (0.6%) | 3 (1.1%) | ||
| NSTEMI | 1474 (51%) | 1358 (52%) | 116 (41%) | ||
| STEMI | 476 (17%) | 433 (17%) | 43 (15%) | ||
| Unstable angina | 908 (32%) | 789 (30%) | 119 (42%) | ||
SD, standard deviation; BMI, body mass index; MI, myocardial infarction; CAD, coronary artery disease; TIA, transient ischemic attack; HR, heart rate; bpm, beats per minute; SBP, systolic blood pressure; DBP, diastolic blood pressure; Crea, first serum creatinine; p50, median; IQR, interquartile range; LVEF, left ventricular ejection fraction; GRACE, global registry of acute coronary events; LBBB, left bundle branch block; NSTEMI, non-ST myocardial infarction; STEMI, ST-elevation myocardial infarction. BMI was missing in 47 subjects, HR in 4 subjects, SBP and DBP in 5 subjects, creatinine in 10 subjects, LVEF was missing in 468 subjects, GRACE in 14 subjects, 64 subjects in CRUSADE risk score. *The ‘discharged diagnosis’ excluded 129 patients that died in-hospital during the index admission while 1 patient had ‘discharged diagnosis’ missing. Percentages might not add up to 100% due to rounding off.
Table 2.
Medication utilization of the acute coronary syndrome cohort stratified by non-steroidal anti-inflammatory drug (NSAID) use.
Table 2.
Medication utilization of the acute coronary syndrome cohort stratified by non-steroidal anti-inflammatory drug (NSAID) use.
| Characteristic, n (%) unless specified otherwise |
All (N = 3,007) |
NSAID use | p-value | |
|---|---|---|---|---|
| No (n = 2,717) |
Yes (n = 290) |
|||
| Prior medications | ||||
| Aspirin | 2,397 (80%) | 2,151 (79%) | 246 (85%) | 0.023 |
| Clopidogrel | 863 (29%) | 762 (28%) | 101 (35%) | 0.015 |
| ACEIs | 1,562 (52%) | 1,437 (53%) | 125 (43%) | 0.002 |
| ARBs | 573 (19%) | 485 (18%) | 88 (30%) | <0.001 |
| Beta blockers | 1,828 (61%) | 1,639 (60%) | 189 (65%) | 0.108 |
| Statins | 2,428 (81%) | 2,186 (80%) | 242 (83%) | 0.219 |
| Other LLDs | 60 (2.0%) | 57 (2.1%) | 3 (1.0%) | 0.273 |
| Oral nitrates | 1,049 (35%) | 670 (42%) | 379 (27%) | <0.001 |
| CCBs | 599 (20%) | 523 (19%) | 76 (26%) | 0.005 |
| H2-receptor antagonists | 410 (14%) | 331 (12%) | 79 (27%) | <0.001 |
| Proton pump inhibitors | 617 (21%) | 527 (19%) | 90 (31%) | <0.001 |
| Discharged medications (N=2,747)* | ||||
| Aspirin | 2,645 (96%) | 2,388 (96%) | 257 (98%) | 0.197 |
| Clopidogrel | 2,009 (73%) | 1,792 (72%) | 217 (83%) | <0.001 |
| ACEIs | 1,795 (65%) | 1624 (65%) | 171 (65%) | 0.907 |
| ARBs | 499 (18%) | 443 (18%) | 56 (21%) | 0.168 |
| Beta blockers | 2,324 (85%) | 2,089 (84%) | 235 (89%) | 0.025 |
| Statins | 2,675 (97%) | 2,414 (97%) | 261 (99%) | 0.050 |
| Other LLDs | 75 (2.7%) | 67 (2.7%) | 8 (3.0%) | 0.745 |
| Oral nitrates | 1,722 (63%) | 1,562 (63%) | 160 (61%) | 0.509 |
| CCBs | 509 (19%) | 462 (19%) | 47 (18%) | 0.770 |
| Dual antiplatelets | 2,705 (98%) | 2,445 (98%) | 260 (99%) | 0.589 |
| 5-drug regimen | 1,427 (52%) | 1,265 (51%) | 162 (62%) | 0.001 |
| H2-receptor antagonists | 582 (21%) | 517 (21%) | 65 (25%) | 0.142 |
| Proton pump inhibitors | 356 (13%) | 315 (13%) | 41 (16%) | 0.183 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; LLD, lipid lowering drug; CCBs, calcium channel blockers; Dual antiplatelets, aspirin and clopidogrel concurrently; 5 drug regimen, concurrent prescribing of aspirin, clopidogrel, ACEI/ARB, statin, beta blocker. The discharged medications excluded those that died in-hospital (n=129) during the index admission as well as those that had missing drug information (n=131), while those on discharged ARB, statins, other LLTs, oral nitrates, CCBs, proton pump inhibitors and H2 receptor blockers had one further patient excluded due to missing drug information. Percentages might not add up to 100% due to rounding off.
Table 3.
Association between non-steroidal anti-inflammatory drug (NSAID) use and 12-month cumulative major adverse cardiovascular events (MACE) in acute coronary syndrome patients in the Arabian Gulf.
Table 3.
Association between non-steroidal anti-inflammatory drug (NSAID) use and 12-month cumulative major adverse cardiovascular events (MACE) in acute coronary syndrome patients in the Arabian Gulf.
| Outcome | Univariate statistics (NSAID use) | Multivariate logistic regression | ||||||
|---|---|---|---|---|---|---|---|---|
| All (N = 2910) | No (n = 2627) | Yes (n = 283) | p-value | Adj. OR [95% CI] | Adj. p-value | HL | ROC | |
| Stroke/TIA | 143 (4.9%) | 115 (4.4%) | 28 (9.9%) | <0.001 | 2.50 [1.51-4.14] | <0.001 | 0.917 | 0.75 |
| Myocardial infarction | 249 (8.6%) | 223 (8.5%) | 26 (9.2%) | 0.690 | 1.26 [0.80-1.99] | 0.320 | 0.102 | 0.71 |
| All-cause Mortality | 395 (13.6%) | 366 (14.0%) | 29 (10.3%) | 0.086 | 0.79 [0.46-1.34] | 0.383 | 0.075 | 0.78 |
| Re-admissions | 823 (28.3%) | 705 (26.8%) | 118 (41.7%) | <0.001 | 2.09 [1.59-2.74] | <0.001 | 0.665 | 0.61 |
| Total MACE | 1195 (41.1%) | 1052 (40.1%) | 143 (50.5%) | 0.001 | 1.89 [1.44-2.48] | <0.001 | 0.391 | 0.67 |
Adj. OR, adjusted odds ratio; CI, confidence interval; HL, Hosmer & Lemeshow p-value; ROC, area under the receiver operating curve (also known as c-statistic); TIA, transient ischemic attack; re-admissions, re-admissions for cardiac reasons. MACE included stroke/TIA, myocardial infarction, mortality and re-admissions for cardiac reasons. For 6-month and 12-month follow-up, the events were cumulative. Multivariate analyses were conducted using logistic regression models utilizing the simultaneous method. The covariates in the models included GRACE risk score (derived from age, heart rate, systolic blood pressure, serum creatinine, cardiac arrest at admission, ST segment deviation on EKG, abnormal cardiac enzymes and Killip class) as well as gender, smoking status, marital status, employment status, education status, body mass index, diabetes mellitus, peripheral artery disease, percutaneous coronary intervention/coronary artery bypass graft, prior event and use of evidence-based cardiac medications at hospital discharge (aspirin, clopidogrel, beta blocker, statin, angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)). Over the 1-year follow-up period, there were losses to follow-up of 97 (3.2%) patients.
Table 4.
Demographic and clinical characteristics between the non-steroidal anti-inflammatory drug group remaining at the end of the year and the cohort that was lost to follow-up (LTF).
Table 4.
Demographic and clinical characteristics between the non-steroidal anti-inflammatory drug group remaining at the end of the year and the cohort that was lost to follow-up (LTF).
| Characteristic, mean±SD unless specified otherwise |
LTF (n = 97) 3.2% |
Remaining (n = 2910) 96.8% |
p-value |
|---|---|---|---|
| Demographic | |||
| Age, years | 62±11 | 62±12 | 0.940 |
| Female gender, n (%) | 38 (39%) | 1,118 (38%) | 0.880 |
| BMI, kg/m2 | 29.4±5.5 | 29.1±7.1 | 0.646 |
| Clinical, n (%) | |||
| Prior MI | 32 (33%) | 994 (34%) | 0.811 |
| Hypertension | 81 (84%) | 2,352 (81%) | 0.509 |
| Diabetes mellitus | 69 (71%) | 1,834 (63%) | 0.103 |
| Stroke/TIA | 8 (8.3%) | 266 (9.1%) | 0.764 |
| Presentation, n (%) | |||
| SBP, mmHg | 143±29 | 142±28 | 0.960 |
| DBP, mmHg | 80±17 | 80±16 | 0.832 |
| Killip ≥2, n (%) | 23 (24%) | 714 (25%) | 0.853 |
| GRACE risk score | 132±41 | 130±42 | 0.668 |
| CRUSADE risk score | 39±15 | 38±15 | 0.603 |
| Major bleeding | 3 (3.1%) | 59 (2.0%) | 0.451 |
| Prior PCI | 30 (31%) | 793 (27%) | 0.424 |
SD standard deviation, BMI body mass index, MI myocardial infarction, TIA, transient ischemic attack, SBP systolic blood pressure, DBP diastolic blood pressure, GRACE global registry of acute coronary events, PCI percutaneous coronary intervention (includes any prior PCI). BMI was missing in 47 subjects, SBP and DBP in 5 subjects, GRACE risk score in 14 subjects and 64 subjects in the CRUSADE risk score. Percentages may not add up too 100% due to rounding off.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
